FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| SGT-003 | Duchenne Muscular Dystrophy | PHASE3 | RECRUITING |
| SGT-212 | Friedreich's Ataxia (FA) | PHASE1 | RECRUITING |
| SGT-501 | Catecholaminergic Polymorphic Ventricular Tachycar | PHASE1 | RECRUITING |
SLDB holds $159.4M in cash and burns about $49.9M/quarter from operations, giving an estimated runway of 9.6 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for SLDB free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-07-07 | SMITH IAN F |
Purchase | $0 |
| 2026-07-07 | SMITH IAN F |
Sale | $0 |
| 2026-06-11 | EDELMAN JOSEPH |
Purchase | $0 |
| 2026-06-11 | SMITH IAN F |
Purchase | $0 |
| 2026-06-11 | Nagendran Sukumar |
Purchase | $0 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for SLDB and 2 more tickers of your choice.
Create Free Account →